ReviewSkin health and disease2026
Prevalence of vitiligo in East Africa: systematic review and meta-analysis.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is a chronic skin disorder characterized by the loss of melanocytes, resulting in depigmented macules and patches. No accurate estimate has been made of the prevalence of vitiligo in East Africa. Objectives: To determine the prevalence of vitiligo in East Africa via a systematic review and meta-analysis of the literature. Methods: A systematic review and meta-analysis were performed in accordance with the PRISMA guidelines. Eleven articles were retrieved from PubMed/MEDLINE, Embase, Scopus, Google Scholar, Science Direct, Web of Science and African Journals Online. Microsoft Excel was used to extract the data, which were then exported to STATA 17 for analysis using a random effects model. Heterogeneity of studies was assessed by Cochran's Results: The 11 studies retrieved from the literature search provided a total sample size of 8444 individuals reported between 2000 and 2025. The overall pooled prevalence of vitiligo was 6% [95% confidence interval (CI) 3-8], while the prevalence among male and female individuals was 54% (95% CI 19-73) and 46% (95% CI 3-61), respectively. The prevalence in children was 3% (95% CI 2-5), 9% (95% CI 7-12) in adults and 7% (95% CI 2-11) in the general population. The models showed that the prevalence of vitiligo in Tanzania was 1% (95% CI 0-3), while the pooled prevalence of vitiligo in Ethiopia was 8% (95% CI 5-11). Conclusions: In East Africa, the combined prevalence of vitiligo was relatively high. The increased prevalence of vitiligo highlights the need for health policymakers to pay attention to vitiligo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.